FBG, HbA1c, and triglycerides (TG) are three key blood tests used in the assessment and monitoring of diabetes and metabolic health in the UK. Fasting blood glucose reflects short-term glucose regulation, HbA1c provides a two-to-three-month average of glycaemic control, and triglycerides indicate how well the body is managing blood fats — all of which are closely linked to insulin resistance. Together, these markers give clinicians a fuller picture of metabolic function, cardiovascular risk, and treatment response. Understanding what each test measures, how NHS reference ranges are applied, and what abnormal results mean can help patients engage more confidently with their diabetes care.

Understanding FBG, HbA1c and Triglycerides in Diabetes Monitoring

FBG, HbA1c, and triglycerides are distinct but complementary tests assessed in UK diabetes care; HbA1c is checked every three to six months, whilst a fasting lipid profile including triglycerides is performed annually as part of the NHS Diabetes Annual Review.

Have any more questions about this? Message our pharmaceutical team to get more info →

Monitoring blood glucose and lipid levels is central to the diagnosis and long-term management of diabetes in the UK. Three key measurements — fasting blood glucose (FBG), glycated haemoglobin (HbA1c), and triglycerides (TG) — may be assessed as part of a comprehensive metabolic evaluation. Each test provides distinct but complementary information, helping clinicians identify risk, guide treatment decisions, and monitor the effectiveness of lifestyle or pharmacological interventions.

Fasting blood glucose reflects the body's ability to regulate blood sugar in the absence of recent food intake, whilst HbA1c offers a longer-term view of glycaemic control over the preceding two to three months. Triglycerides, a type of blood fat, are closely intertwined with glucose metabolism and insulin resistance. Elevated triglyceride levels are commonly observed alongside poor glycaemic control, making them a valuable additional marker in diabetes care.

It is important to note that these tests are not always requested simultaneously in routine NHS practice. HbA1c is typically checked every three to six months in people with established diabetes, whilst a fasting lipid profile — including triglycerides — is usually performed annually as part of the NHS Diabetes Annual Review. Fasting blood glucose is used primarily in specific diagnostic contexts rather than for routine ongoing monitoring once diabetes is confirmed. In the UK, testing and interpretation are guided by frameworks from the National Institute for Health and Care Excellence (NICE) and supported by clinical standards from organisations such as Diabetes UK. Understanding what these tests measure, how results are interpreted, and what action may be needed empowers patients to engage more meaningfully with their care.

What These Blood Tests Measure and Why They Matter

FBG measures post-absorptive blood sugar regulation, HbA1c reflects average glucose over 90–120 days, and triglycerides indicate blood fat levels closely linked to insulin resistance and cardiovascular risk.

Fasting blood glucose (FBG) measures the concentration of glucose in the blood after a period of fasting — typically at least eight hours. It reflects how well the body manages blood sugar in a resting, post-absorptive state. In healthy individuals, insulin secreted by the pancreatic beta cells keeps fasting glucose within a narrow range. In type 2 diabetes or prediabetes, impaired insulin secretion or insulin resistance causes this level to rise.

HbA1c (glycated haemoglobin) measures the proportion of haemoglobin molecules that have glucose attached to them. Because red blood cells have a lifespan of approximately 90–120 days, HbA1c provides a reliable average of blood glucose levels over that period. It is less susceptible to short-term fluctuations caused by recent meals, illness, or stress, making it particularly useful for assessing overall glycaemic control and treatment response.

Triglycerides are the most common form of fat found in the bloodstream. After eating, the body converts unused calories into triglycerides, which are stored in fat cells and released for energy between meals. Chronically elevated triglyceride levels — known as hypertriglyceridaemia — are associated with:

• Insulin resistance and type 2 diabetes

• Metabolic syndrome

• Increased cardiovascular risk

• Non-alcoholic fatty liver disease (NAFLD; increasingly referred to as metabolic dysfunction-associated steatotic liver disease, or MASLD, in recent clinical consensus)

Together, these three markers can provide a more complete assessment of metabolic function than any single test alone, which is why clinicians may request them as part of a combined panel in appropriate clinical circumstances.

How FBG and HbA1c Results Are Interpreted on the NHS

A fasting blood glucose of 7.0 mmol/L or above or an HbA1c of 48 mmol/mol or above confirms diabetes under NICE guidance; results between these thresholds indicate prediabetes and require repeat testing.

In the UK, NICE guidance (NG28) and WHO 2011 recommendations provide clear thresholds for interpreting FBG and HbA1c results in the context of diabetes diagnosis and monitoring. Understanding these reference ranges helps patients make sense of their results and the clinical decisions that follow.

Fasting blood glucose (FBG) reference ranges:

• Normal: below 6.1 mmol/L

• Impaired fasting glucose (prediabetes): 6.1–6.9 mmol/L

• Diabetes: 7.0 mmol/L or above (confirmed on two separate occasions, or once if symptoms of diabetes are present)

HbA1c reference ranges:

• Normal: below 42 mmol/mol (6.0%)

• Prediabetes / high risk: 42–47 mmol/mol (6.0–6.4%)

• Diabetes: 48 mmol/mol (6.5%) or above

For people already diagnosed with type 2 diabetes, NICE recommends an HbA1c target of 48 mmol/mol for those managed by lifestyle alone or with metformin. A target of 53 mmol/mol is generally recommended for those taking medicines that carry a risk of hypoglycaemia (such as insulin or sulfonylureas). Individual targets may vary further depending on age, frailty, comorbidities, and treatment regimen, and should always be agreed with your care team.

When HbA1c should not be used for diagnosis HbA1c is not appropriate for diagnosing diabetes in the following situations, and an alternative test (such as FBG or an oral glucose tolerance test, OGTT) should be used instead:

• Pregnancy or within two weeks of delivery

• Children and young people

• Suspected type 1 diabetes or rapid-onset diabetes

• Conditions affecting red blood cell turnover, such as haemolytic anaemia, haemoglobinopathies (e.g., sickle cell disease, thalassaemia), iron deficiency anaemia, or recent blood transfusion

Results should always be interpreted in clinical context. A single abnormal reading does not automatically confirm a diagnosis, and repeat testing is standard NHS practice before a formal diagnosis of diabetes or prediabetes is made.

The Link Between Triglyceride Levels and Blood Glucose Control

Poor glycaemic control drives elevated triglycerides via insulin resistance, which increases hepatic VLDL production and reduces lipoprotein lipase activity; improving glucose control typically lowers triglyceride levels concurrently.

The relationship between triglycerides and blood glucose is bidirectional and well established in clinical literature. Poor glycaemic control — reflected in elevated FBG and HbA1c — is frequently accompanied by raised triglyceride levels, and this combination significantly amplifies cardiovascular risk.

The underlying mechanism involves insulin resistance. When cells become resistant to insulin, the liver compensates by increasing the production of very low-density lipoprotein (VLDL) particles, which are rich in triglycerides. Simultaneously, the clearance of triglycerides from the bloodstream is impaired due to reduced activity of lipoprotein lipase, an enzyme that normally breaks down circulating fats. The result is a sustained elevation in serum triglycerides.

Triglyceride levels — UK clinical categories:

• Desirable: below 1.7 mmol/L

• Mild elevation: 1.7–2.2 mmol/L

• Moderate elevation: 2.3–4.9 mmol/L

• Severe elevation: 5.0 mmol/L or above — warrants prompt review; address secondary causes (e.g., poor glycaemic control, alcohol, hypothyroidism, certain medicines) and consider specialist lipid clinic referral if levels persist

• Very high / urgent: above 10 mmol/L — associated with a significantly increased risk of acute pancreatitis; seek urgent medical assessment

In most NHS settings, lipid profiles — including triglycerides — are measured from a non-fasting blood sample, which is acceptable for routine cardiovascular risk assessment per NICE NG238. A fasting sample may be requested if non-fasting triglycerides are markedly raised or if severe hypertriglyceridaemia is suspected.

Importantly, improving blood glucose control — through dietary changes, increased physical activity, or medication — often leads to a concurrent reduction in triglyceride levels. Conversely, persistently elevated triglycerides may signal that glycaemic management needs to be reviewed. Alcohol intake, a high-carbohydrate diet, obesity, and hypothyroidism are additional factors that can raise triglycerides independently of diabetes, and these should be considered when interpreting results.

When Your GP May Request These Tests Together

GPs may request FBG, HbA1c, and triglycerides together during routine diabetes reviews, cardiovascular risk assessments, suspected metabolic syndrome, or when monitoring medicines known to raise blood glucose and lipids.

GPs and practice nurses in the UK may request FBG, HbA1c, and triglycerides as part of a combined metabolic or cardiovascular risk assessment in specific clinical circumstances. It is worth noting that these tests are not always ordered simultaneously in routine care — testing intervals and indications differ.

Common reasons for combined or related testing include:

• Routine diabetes review: People with type 2 diabetes typically have HbA1c checked every three to six months. A full lipid profile — including triglycerides — is assessed annually as part of the NHS Diabetes Annual Review.

• Suspected prediabetes or metabolic syndrome: Patients presenting with central obesity, hypertension, or a family history of type 2 diabetes may be screened with a combined panel.

• Cardiovascular risk assessment: NICE guidelines recommend using tools such as QRISK3 to estimate ten-year cardiovascular risk. QRISK3 incorporates variables including age, sex, blood pressure, smoking status, cholesterol-to-HDL ratio, diabetes status, kidney disease, and other clinical factors — it uses a recorded diagnosis of diabetes rather than individual glucose or HbA1c values.

• Monitoring medication effects: Certain medicines — including corticosteroids, antipsychotics, and some antiretrovirals — can raise both blood glucose and triglycerides, warranting combined monitoring.

• Unexplained fatigue or weight changes: These symptoms may prompt a broad metabolic screen.

For most lipid tests, including triglycerides, a non-fasting sample is acceptable. Your GP or practice nurse will advise you if a fasting sample is specifically required. If you are unsure, confirm with your GP surgery before your appointment. Water is always permitted during any fasting period.

Managing Abnormal Results: NHS Guidance and Next Steps

NICE recommends lifestyle modification — including dietary changes, physical activity, and weight management — as the first step for abnormal FBG, HbA1c, or triglyceride results, with metformin or other pharmacological agents added if lifestyle measures are insufficient.

Receiving abnormal results for FBG, HbA1c, or triglycerides can feel concerning, but it is important to understand that these findings are manageable — particularly when identified early. NHS guidance emphasises a structured, stepwise approach to treatment, beginning with lifestyle modification before escalating to pharmacological intervention where necessary.

Lifestyle interventions recommended by NICE include:

• Dietary changes: Reducing refined carbohydrates, added sugars, saturated fats, and alcohol; increasing fibre intake through vegetables, pulses, and wholegrains

• Physical activity: At least 150 minutes of moderate-intensity aerobic activity per week, as recommended by NHS guidelines

• Weight management: Even a modest weight loss of 5–10% of body weight can significantly improve FBG, HbA1c, and triglyceride levels

• Smoking cessation: Smoking worsens insulin resistance and cardiovascular risk

If lifestyle measures are insufficient, your GP may consider pharmacological treatment. Key points from NICE guidance (NG28) include:

• Metformin remains the standard first-line medication for type 2 diabetes, improving insulin sensitivity and reducing hepatic glucose production

• SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) are recommended by NICE for people with established cardiovascular disease or chronic kidney disease, in addition to metformin

• Statins are the priority treatment for reducing overall cardiovascular risk in people with diabetes

• For significantly elevated triglycerides, fibrates and omega-3 fatty acid preparations are generally initiated by specialist lipid services rather than in primary care. Icosapent ethyl is recommended by NICE (TA805) for selected high-risk patients already on statin therapy

HbA1c targets should be individualised. A target of 53 mmol/mol is generally appropriate for those on therapies associated with hypoglycaemia risk (e.g., insulin, sulfonylureas). For older or frailer patients, or those with significant comorbidities, less stringent targets may be agreed with the care team.

When to contact your GP:

• HbA1c at or above 48 mmol/mol on repeat testing, or FBG consistently at or above 7.0 mmol/L

• Triglycerides between 5.0 and 10 mmol/L — your GP will recheck levels after addressing secondary causes (e.g., alcohol, poor glycaemic control) and may refer to a specialist lipid clinic if levels persist

Seek urgent medical attention (call 999 or go to A&E) if you experience:

• Severe abdominal pain radiating to the back, with nausea or vomiting — this may indicate acute pancreatitis, which is associated with very high triglyceride levels (typically above 10 mmol/L)

• Symptoms of a hyperglycaemic emergency, such as marked drowsiness, severe dehydration, rapid breathing, or the smell of ketones on the breath

Regular follow-up is essential. Your GP or diabetes care team will agree individualised targets and review intervals based on your overall health profile, ensuring that management remains both safe and effective.

If you believe a medicine may be causing side effects — including changes to your blood glucose or lipid levels — you can report this to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions